Elicio Therapeutics
Biotechnology, 1 Kendall Sq, Boston, Massachusetts, 02139, United States, 11-50 Employees
Phone Number: 16*********
Who is ELICIO THERAPEUTICS
Elicio is committed to transforming the lives of patients and their families by re-engineering the bodys immune response to cancer. By combining expertise in materials science and immunol...
Read More
- Headquarters: 1 Kendall Sq, Boston, Massachusetts, 02139, United States
- Employees: 11-50
- Revenue: $10 Million to $25 Million
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from ELICIO THERAPEUTICS
Elicio Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Elicio Therapeutics
Answer: Elicio Therapeutics's headquarters are located at 1 Kendall Sq, Boston, Massachusetts, 02139, United States
Answer: Elicio Therapeutics's phone number is 16*********
Answer: Elicio Therapeutics's official website is https://elicio.com
Answer: Elicio Therapeutics's revenue is $10 Million to $25 Million
Answer: Elicio Therapeutics's SIC: 2834
Answer: Elicio Therapeutics has 11-50 employees
Answer: Elicio Therapeutics is in Biotechnology
Answer: Elicio Therapeutics contact info: Phone number: 16********* Website: https://elicio.com
Answer: Elicio is committed to transforming the lives of patients and their families by re-engineering the bodys immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the brain center of the immune response, to significantly amplify and enhance the bodys own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio's lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicios Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month